Thomas James Doyle sold $39k of KURA
SVP, Finance & Accounting at Kura Oncology, Inc.. 4,949 shares at an average of $7.87, traded Jan 28, 2025, filed Jan 28, 2025.
Score components
- +15RoleOfficer
- +6Trade size$39k at market
- 0Share of holdings soldSold 5.3% of holdings
- +15Cluster6 insiders selling within 14 days
What happened after comparable sells
Same side and tier, against the S&P 500, at 1, 3 and 6 months. Shown to Pro users; the whole table is on the backtest page.
Price around the trade, and since
From a quarter before the trade to today. The arrow is the trade, the circle the day the filing reached EDGAR, which is the first day anyone outside could act; the dotted line is the S&P 500 rebased to that day's close.
Daily candles, adjusted for splits and dividends. Green arrows are insider buys, red are sells, sized by value; the dashed line is the close on the filing day, the dotted line SPY rebased to it.Charts by TradingView Lightweight Charts™
Rows in this filing
Every transaction in Form 4 0000950170-25-010137, as filed. Open on EDGAR
| Date | Transaction | Shares | Price | Value | Holdings after | Filed |
|---|---|---|---|---|---|---|
| Jan 28, 2025 | SOpen-market sale Common Stock | -2,241 | $7.87 | $18k | 90,901 | Jan 28, 2025 |
| Jan 28, 2025 | SOpen-market sale Common Stock | -887 | $7.87 | $6,982 | 90,014 | Jan 28, 2025 |
| Jan 28, 2025 | SOpen-market sale Common Stock | -699 | $7.87 | $5,502 | 89,315 | Jan 28, 2025 |
| Jan 28, 2025 | SOpen-market sale Common Stock | -1,122 | $7.87 | $8,832 | 88,193 | Jan 28, 2025 |
Related signals
Other insiders at Kura Oncology, Inc. and this insider’s other filings.
| Score | Company | Insider | Value | Holdings | Filed |
|---|---|---|---|---|---|
| 19Weak | Kura Oncology, Inc. | Teresa Brophy Bair Chief Legal Officer | $89k 8,442 shares | -4% | |
| 37Weak | Kura Oncology, Inc. | Thomas James Doyle SVP, Finance & Accounting | $48k 4,607 shares | -3% | |
| 25Weak | Kura Oncology, Inc. | Kathleen Ford Chief Operating Officer | $112k 10,574 shares | -7% | |
| 30Weak | Kura Oncology, Inc. | Brian T. Powl Chief Commercial Officer | $345k 32,450 shares | -19% | |
| 32Weak | Kura Oncology, Inc. | Mollie Leoni Chief Medical Officer | $440k 41,250 shares | -23% | |
| 37Weak | Kura Oncology, Inc. | Francis Burrows Chief Scientific Officer | $225k 20,726 shares | -33% | |
| 0Weak | Kura Oncology, Inc. | Teresa Brophy Bair Chief Legal Officer | $21k 2,256 shares | -1% | |
| 40Moderate | Kura Oncology, Inc. | Teresa Brophy Bair Chief Legal Officer | $95k 11,208 shares | -5% | |
| 30Weak | Kura Oncology, Inc. | Francis Burrows Chief Scientific Officer | $11k 1,311 shares | -4% | |
| 37Weak | Kura Oncology, Inc. | Thomas James Doyle SVP, Finance & Accounting | $60k 7,142 shares | -5% |
Not investment advice. Scores and forward returns are decision support built from public SEC filings and past prices; they describe what happened after comparable filings, not what will happen after this one. Do your own research and size your risk.